Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 57Leukemia, Lymphocytic, Chronic, B-Cell 30Myelodysplastic Syndromes 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia, Myelomonocytic, Chronic 15Myeloproliferative Disorders 12Lymphoma 12Leukemia, Biphenotypic, Acute 11Burkitt Lymphoma 11Lymphoma, Follicular 9Leukemia 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic-Myeloproliferative Diseases 8Hematologic Neoplasms 8Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, B-Cell, Marginal Zone 7Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Leukemia, Monocytic, Acute 5Anemia, Refractory, with Excess of Blasts 5Lymphoma, T-Cell, Cutaneous 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Congenital Abnormalities 4Lymphoma, T-Cell 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Myelomonocytic, Acute 3Leukemia, Hairy Cell 3

Interventions

trametinib 2fludarabine 2thymoglobulin 1omipalisib 1fludarabine phosphate 1Rituximab 1Melphalan 1Levetiracetam 1Injections 1Cytarabine 1Cyclophosphamide 1Busulfan 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × Biopsy × Other hematologic neoplasm × Clear all
NCT03190915 2026-05-27

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
10 enrolled 11 charts
CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡